Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyVisceral SurgeryDiseaseBreast CancerGastric CancerOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupEpCAM positiveICD10C16.-C16.0C50.-C56C78.6MeSHBreast NeoplasmsCarcinoma, Ovarian EpithelialOvarian NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceAntineoplastic therapySubstanceCatumaxomabNaCl 0.9%SubstanceCatumaxomabNaCl 0.9%SubstanceCatumaxomabNaCl 0.9%SubstanceCatumaxomabNaCl 0.9%No. Substances2 RadiotherapySupportive therapySubstanceGranisetronNaCl 0.9%ParacetamolSubstanceGranisetronNaCl 0.9%ParacetamolSubstanceGranisetronNaCl 0.9%ParacetamolSubstanceGranisetronNaCl 0.9%ParacetamolNo. Substances3Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Increase AminotransferasesLymphopeniaPyrexia only studiesPublicationAuthorHeiss MMDiseasePeritonealkarzinose, sekundär, EpCAM positivOriginCologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyProtocols in Revision 1 protocol foundCatumaxomab (10/20/50/150), Peritoneal Carcinomatosis, Secondary (PID3037 V1.0)
